Among the 16 patients with RET fusion-positive NSCLC in the IMMUNOTARGET registry, the median OS from the start of ICI therapy was 21.3 (3.8; 28.0), and the median PFS was only 2.1 (1.3; 4.7) (31). This evidence concerns the gene RET and non-small cell lung carcinoma.